Introduction
Mitogen-activated protein (MAP) kinases have been implicated in many physiological processes, including cell proliferation, dierentiation, and death. These processes are relevant to the development and function of T cells. Here we will review recent progress that has established roles for MAP kinases in T cell development and function.
There are three major groups of MAP kinases in mammalian cells, the extracellular signal-regulated protein kinases (ERK) (Schaeer and Weber, 1999) , the p38 MAP kinases (Han and Ulevitch, 1999) , and the c-Jun NH 2 -terminal kinases (JNK) (Davis, 2000) ( Figure 1 ). These MAP kinases are activated by dual phosphorylation on the tripeptide motif Thr-Xaa-Tyr. The sequence of this tripeptide motif is dierent in each group of MAP kinases: ERK (Thr-Glu-Tyr); p38 (Thr-Gly-Tyr); and JNK (Thr-Pro-Tyr). The dual phosphorylation of Thr and Tyr is mediated by a conserved protein kinase cascade. The ERK MAP kinases are activated by the MAP kinase kinases MKK1 and MKK2; the p38 MAP kinases are activated by MKK3, MKK4, and MKK6; and the JNK pathway is activated by MKK4 and MKK7. These MAP kinase kinases are activated, in turn, by several dierent MAP kinase kinase kinases (MAPKKK). Dierent upstream signals can lead to the activation of these MAPKKK. However, prominent roles for small G proteins have been identi®ed. Thus, the ERK pathway can be activated by Ras via the Raf group of MAPKKK. In contrast, the p38 and JNK MAP kinases are activated by Rho family GTPases, including Rac and Cdc42. Candidate MAPKKK that are activated by Rho proteins include members of the MEKK and mixed-lineage protein kinase groups.
The ERK, p38, and JNK groups of MAP kinases are present in T cells. These protein kinases are activated by the same protein kinase cascades that lead to MAP kinase activation in other cell types. However, the mechanisms that activate these MAP kinase cascades are distinctive in T cells. For example, activation of the T cell receptor (TcR) can cause increased ERK activation, while co-stimulation by accessory molecules (e.g. CD28) is required for JNK activation . It remains unclear how upstream signals triggered by the TcR modulate the MAP kinase signaling pathways. Although a role for calcineurin and protein kinase C theta has also been proposed , more recent studies have shown that protein kinase C theta is not required for JNK activation in T cells (Sun et al., 2000) . It is therefore unclear how CD28-mediated signals integrate with TcR-mediated signals to control activation of the MAP kinase pathways. However, signal integration may involve co-operation between Syk and Rac . Indeed, gene disruption studies demonstrate that the Rac2 gene is required for activation of JNK and p38 MAP kinase (Li et al., 2000) . (reviewed by Rodewald and Fehling, 1998) (Figure  2 ). Down-modulation of CD25 from the cell surface is associated with the expression of the pre-TcR, which is formed by the association of the TcRb chain with gp33/pre-Ta. Signals mediated by the preTcR complex induce proliferation and dierentiation of DN thymocytes into CD4 + CD8
Role of MAP kinases in early thymocyte development
+ double positive (DP) cells, TcRa chain rearrangements and TcRb allelic exclusion.
Several studies have examined the role of the ERK1/2 pathway in early thymocyte development. Retrovirus infection of fetal thymic organ cultures (FTOC) with dominant-negative and constitutivelyactivated MEK1 (the upstream activator of ERK1/2) mutants showed that activation of the ERK pathway is required for dierentiation of immature CD25 + CD44
7 thymocytes . Moreover, anti-CD3 monoclonal antibody (Mab) activates ERK in these immature thymocytes, suggesting that the ERK pathway acts as a transducer of the pre-TcR . More recently, it has been demonstrated that this is indeed the case since expression of the TcRb chain in RAG2 7/7 FTOC assays by gene gun transfection results in the activation of ERK (Michie et al., 1999) . Furthermore, activation of the ERK pathway by expression of a constitutively-activated form of c-Raf-1 in transgenic mice induces maturation and expansion of RAG2 7/7 CD25 7
CD44
7 thymocytes but not allelic exclusion in the absence of the pre-TcR (Iritani et al., 1999) . Thus, dierentiation and proliferation of immature thymocytes by the pre-TcR is mediated by the ERK signaling pathway, but additional pre-TcR signals mediate TcRb allelic exclusion.
Although studies of JNK1 or JNK2 de®cient mice have not provided evidence for a function of JNK in early thymocyte development (Dong et al., 1998; Sabapathy et al., 1999a Sabapathy et al., , 2001 Yang et al., 1998) , further analysis is needed to examine whether JNK may regulate maturation, expansion or death of DN thymocytes under normal physiological conditions.
A high level of p38 MAP kinase activity, but not JNK activity, is found in freshly isolated thymocytes (Sen et al., 1996) . Analysis of p38 MAP kinase activity in dierent subpopulations of DN thymocytes has shown that p38 MAP kinase was activated in CD25 
7 subset . This dierence in p38 MAP kinase activity is likely to be physiologically signi®cant for thymocyte development. This conclusion is supported by the ®nding that the in vivo expression of a constitutivelyactivated form of MKK6, an upstream activator of p38 MAP kinase, completely blocks early thymocyte dierentiation during fetal development (day E16-17) at the CD8
7 stage . The blockade of thymocyte development results in a marked reduction of CD4 + and CD8 + T cells in the periphery of the adult mice. Although the total number of thymocytes is reduced in transgenic embryos and young mice, the continuous entry of new cohorts of precursor cells into the thymus and the dierentiation and expansion of CD25
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CD44
+ and CD25 + CD44 + thymocytes causes a slow but progressive accumulation of these immature cells within the thymus . This observation contrasts with the phenotype of mice de®cient in components of the pre-TcR (e.g. RAG2, lck, preTa, in which thymocyte development is also arrested at the CD25 + CD44
7 stage, but in these cases thymocytes do not accumulate despite the continuous entry of new precursors into the thymus (Rodewald and Fehling, 1998) . Persistent activation of p38 MAP kinase not only prevents dierentiation of CD25 + CD44
7 immature thymocytes but also inhibits cell cycle progression, since large numbers of thymocytes in these transgenic mice were arrested in mitosis . Similarly in Xenopus, microinjection of activated MKK6 in embryonic blastomeres causes mitotic arrest (Takenaka et al., 1998) . Studies of other cell types indicate that growth arrest caused by activated p38 MAPK may also be mediated by decreased expression of cyclin D1 (Awad et al., 2000; Lavoie et al., 1996) . The identi®cation of the molecular mechanism by which p38 MAP kinase causes growth arrest in thymocytes remains to be established.
Inhibition of p38 MAP kinase also causes defects in early thymocyte development. Thus, the expression of a dominant-negative form of p38 MAP kinase in transgenic mice using the proximal lck promoter results in reduced numbers of DN, DP and single positive (CD4 and CD8) thymocytes. This observation suggests that p38 MAP kinase is required for early expansion of very immature thymocytes . However, inactivation of p38 MAP kinase is required for dierentiation and proliferation of immature CD25 + CD44
7 thymocytes . Together, these data indicate that strict regulation of p38 MAP kinase activity is critical for early T cell development in the thymus.
Role of MAP kinases in positive/negative selection and lineage commitment of thymocytes
Pre-TcR signals dictate dierentiation of DN into DP thymocytes. DP cells undergo both positive and negative selection. These processes involve signals delivered by the interaction of the TcR with the corresponding major histocompatibility complex (MHC), and additional signals provided by stromal cells. As a result of these processes, and the downmodulation of either CD4 or CD8 co-receptors (lineage commitment), DP thymocytes dierentiate into mature single CD4 + or CD8 + thymocytes. Several studies using dierent transgenic mouse models and retrovirus infection have shown that the Ras/Raf-ERK pathway is required for positive selection of DP thymocytes O'Shea et al., 1996; Sugawara et al., 1998; Swan et al., 1995; Swat et al., 1996) . This conclusion is consistent with the observation that CD3d 7/7 DP thymocytes fail to undergo positive selection due to their inability to activate ERK upon TcR engagement, whereas the activation of the other MAP kinases is unaected (Delgado et al., 2000) . Moreover, studies of ERK1 de®cient mice indicate reduced percentages of mature CD4 + and CD8 + thymocytes (Pages et al., 1999) . Together, these data demonstrate that the ERK MAP kinase signaling pathway contributes to positive selection of DP thymocytes.
In contrast to positive selection, inhibition of the ERK pathway in vivo does not aect negative selection (Alberola-Ila et al., 1996) . However, a role for the ERK pathway in models of in vitro negative selection using FTOC assays has been reported (Bommhardt et al., 2000; Mariathasan et al., 2000) . These studies rely on the use of drugs that inhibit ERK activation. Consequently, de®nitive conclusions can not be drawn from these studies. This is because the eect of pharmacological inhibitors on negative selection in FTOC assays may be caused by an indirect inhibition of the ERK pathway in stromal cells (e.g. macrophages, epithelial, dendritic cells) instead of thymocytes. Furthermore, these drugs are not speci®c for the ERK1/2 pathway because the ERK5 pathway is also inhibited.
The possible role of p38 MAP kinase in positive and negative selection is controversial. One report indicates that pharmacological inhibition of p38 MAP kinase in FTOC assays does not aect positive selection, but does block anti-CD3 and antigeninduced deletion of DP thymocyte in vitro (Sugawara et al., 1998) . Moreover, over-expression of wild type MKK6 in FTOC assays by retrovirus infection results in deletion of DP thymocytes (Sugawara et al., 1998) . In contrast, in a dierent study, pharmacological inhibition of p38 MAP kinase in FTOC assays was reported to prevent dierentiation of DP cells into mature single CD4 + and CD8 + thymocytes (positive selection) in vitro (Fernandez, 2000) . A third study indicates that transgenic expression of constitutivelyactivated MKK6 or dominant-negative p38 DP and mature thymocytes (not in DN thymocytes) in vivo does not aect cell number or the percentage of thymocyte sub-populations RincoÂ n et al., 1998a) . On balance, it appears that the evidence for a role of p38 MAP kinase in negative selection is not strong. Further studies are required to rigorously examine this issue.
JNK has also been implicated in negative selection, but does not appear to contribute to the regulation of positive selection. JNK is activated in DP thymocytes upon in vivo treatment with anti-CD3 Mab, which causes deletion of DP thymocytes (RincoÂ n et al., 1998b) . Inhibition of JNK in transgenic mice expressing a dominant-negative form of JNK1 results in a delayed elimination and accelerated reconstitution of DP thymocytes in response to anti-CD3 Mab administration in vivo (RincoÂ n et al., 1998b) . Recently, this role of the JNK pathway has been con®rmed in studies of mice de®cient of JNK1 or JNK2 (Sabapathy et al., 1999a . Although these studies indicate that the activation of JNK mediates deletion of DP thymocytes in vivo, further studies are needed to demonstrate that JNK is required for negative selection of autoreactive T cells in the thymus and that the lack of this signaling pathway results in autoimmune diseases.
The potential role of JNK and p38 MAP kinases in the decision of DP thymocytes to become CD4 + or CD8 + thymocytes and mature naõÈ ve CD4 + and CD8 + T cells (e.g. lineage commitment) remains unknown. However, over-expression of a hypersensitive form of ERK2 biases dierentiation towards the CD4 + T cell lineage (Sharp et al., 1997) . Recent studies have also shown that pharmacological inhibition of the ERK pathway modi®ed signals that normally induce CD4 + thymocyte dierentiation to instead promote CD8 + development in vitro (Bommhardt et al., 1999; Sharp and Hedrick, 1999) . Thus, the ERK signaling pathway may play an important role in both positive selection and lineage commitment.
Signal transduction by MAP kinases in T lymphocytes M Rinco Ân et al
Role MAP kinases in CD4 + T cell activation and dierentiation NaõÈ ve (precursor) CD4 + helper T (Th) cells recognize speci®c MHC-peptide complexes on antigen presenting cells (APC) via the T cell receptor (TcR) complex. In addition to the TcR-mediated signal, a second signal is also required for activation. This co-stimulatory signal is provided by accessory molecules (B7 molecules) expressed on APC that bind CD28 or CTLA-4 which are expressed on T cells. The combination of the two signals induces IL-2 production, IL-2 receptor expression and T cell clonal expansion. After 4 ± 5 days of proliferation, precursor CD4 + T cells dierentiate intò armed eector Th cells' which mediate the speci®c functions of the immune system (Figure 3) . Two subsets of eector Th cells have been de®ned on the basis of their distinct cytokine secretion patterns and their immunomodulatory eects: Th1 cells produce IFNg and LT (TNFb), which are required for cell-mediated in¯ammatory reactions; Th2 cells secrete IL-4, IL-5, IL-6, IL-10 and IL-13, which mediate B cell activation and dierentiation (reviewed by Paul and Seder, 1994) . The selective dierentiation of precursor CD4 + T into Th1 and Th2 cells is established during the initial priming of these cells and is in¯uenced by a variety of extracellular factors, such as the cytokine environment (Constant and Bottomly, 1997) . The balance of Th1 and Th2 immune responses in¯uence the progression of a large number of diseases.
The role of JNK in CD4 + T cell activation and IL-2 expression has been studied intensively. However, the contribution of the JNK signaling pathway to these processes has not been resolved. An important role for JNK is implicated by observations made using Jurkat cells which indicate that co-stimulation (anti-CD3 plus anti-CD28) is required for both JNK activation and IL-2 expression . Studies of Jurkat cells also indicate that JNK may contribute to the regulation of IL-2 gene transcription (Matsuda et al., 1998) and to IL-2 mRNA stability (Chen et al., 1998) . Regulation of the IL-2 promoter could be mediated by several transcription factors, including NF-kB, AP-1, and NFAT. The regulation of IL-2 mRNA stability involves a cis-element (JER) encompassing the 5' untranslated region (Chen et al., 1998) . Two major RNA binding proteins (nucleolin and YB-1) that bind to the JER element in vitro have been identi®ed and the binding of both proteins is required for JNK-induced stabilization of IL-2 mRNA in a cell-free system . Together, these studies suggest that JNK may contribute to activation and IL-2 expression by Jurkat cells.
Studies of T cells isolated from transgenic and knockout mice have been used to test the role of JNK. Normal levels of IL-2 production by JNK1 or JNK2 de®cient splenocytes were reported (Dong et al., 1998; Yang et al., 1998) . JNK2 de®cient CD4 + T cells isolated by negative antibody selection in vitro also express normal levels of IL-2 (Conze and RincoÂ n, unpublished data). In contrast, a dierent study of JNK1 or JNK2 de®cient mice that were independently generated demonstrated that IL-2 production in response to a sub-optimal dose of anti-CD3 plus anti-CD28 Mabs was reduced, but normal levels of Il-2 production were observed in response to an optimal stimulus, in experiments using cultures of mixed CD4 + and CD8 + T cells that were isolated by positive antibody selection in vitro (Sabapathy et al., 1999a ). These dierences may result from the design of the knockout strategies; the dierent methods used for T cell isolation (negative versus positive selection using antibodies); the use of puri®ed or mixed cell populations; and the pathogen status of the mice. Nevertheless, there is agreement amongst these reports that while JNK may contribute to IL-2 expression in response to low level stimulation, JNK does not appear to be required for IL-2 expression in response to high levels of immune challenge.
Mice de®cient of both JNK1 and JNK2 die in utero (Kuan et al., 1999; Sabapathy et al., 1999b) . It is therefore not possible to obtain mice that completely lack expression of JNK. However, CD4 + T cells without JNK can be isolated from Rag1 7/7 mice reconstituted with Jnk1
7/7
Jnk2 7/7 embryonic stem cells; these cells were found to express normal or slightly increased amounts of IL-2 . This observation suggests that JNK is not required for IL-2 expression. Additional evidence to support this ®nding was obtained from the analysis of knockout mice that lack expression of the MAP kinase kinases that activate JNK (MKK4 and MKK7). Both of these knockout mice die in utero, but studies of T cells have been performed using reconstituted mice. MKK4 does not appear to be required for JNK activation in T cells, suggesting that the eects of MKK4 de®ciency on IL-2 expression and lymphadenopathy are JNKindependent (Nishina et al., 1997; Swat et al., 1998) . In contrast, MKK7 de®ciency markedly reduces JNK activity in T cells . This observation suggests that MKK7 may be the primary activator of JNK in T cells. Interestingly, puri®ed Mkk7 7/7 CD4 + T cells were found to produce normal amounts of IL-2 (Dong et al., 2000) . These data do not support the (Weiss et al., 2000) . This regulation of Jnk1 and Jnk2 gene expression represents a novel regulatory mechanism for the JNK pathway. Since IL-2 secretion precedes upregulation of JNK expression, it is dicult to envisage how JNK contributes to early induction of IL-2 gene expression and provides additional support to the conclusion that JNK is not required for IL-2 production by CD4 + T cells. Unlike CD4 + T cell activation, the eector function of CD4 + T cells does appear to be regulated by JNK (Dong et al., 1998 Yang et al., 1998) . JNK2-de®cient CD4 + T cells produce less IFNg during dierentiation in vitro and, consequently, Th1 dierentiation is impaired . The defect in IFNg expression contributes to a marked reduction in the expression of the b2 subunit of the IL-12 receptor . Another study has also described reduced IFNg production by Jnk2 7/7 total T cells (Sabapathy et al., 1999a) , although it is not clear whether this was due to the inability of CD4 + , CD8 + or both T cell subsets to produce IFNg. Th2 dierentiation by Jnk2 7/7 CD4 + T cells was not aected . In contrast, CD4 + T cells from JNK1 de®cient mice selectively dierentiate to become Th2 eector cells in vitro (Dong et al., 1998) . Consistent with this, JNK1 de®cient mice display an enhanced Th2 response against Leishmania major, which renders these mice unable to resolve the infection (Constant et al., 2000) .
The p38 MAP kinase pathway has been implicated in the expression of IL-2 by Jurkat T cells (Matsuda et al., 1998) . In contrast, p38 MAP kinase does not appear to be required for IL-2 production and proliferation of CD4 + T cells (RincoÂ n et al., 1998a). However, using two complementary transgenic mouse systems and a pharmacological inhibitor of p38 MAP kinase, it has been demonstrated that p38 MAP kinase activation is required for IFNg production by Th1 cells, but it is not required for IL-4 and IL-5 production by Th2 cells (RincoÂ n et al., 1998a) . High levels of p38 MAP kinase are induced in Th1, but not in Th2, CD4 + T cells (RincoÂ n et al., 1998a) . In correlation with these results, it has recently been shown that Rac2 induces the IFNg promoter through a cooperative activation of NF-kB and p38 MAP kinase. Rac2 is selectively expressed in Th1 cells, but not in Th2 cells, and IFNg production by Th1 cells from Rac2 de®cient mice is decreased (Li et al., 2000) . Moreover, IL-12 activates p38 MAP kinase and this activity is required for IL-12-induced IFNg expression, probably through phosphorylation of STAT4 (Visconti et al., 2000; Zhang and Kaplan, 2000) . Thus, the p38 MAP kinase pathway plays an important role during murine Th1 dierentiation. In human T cells, pharmacological inhibition of p38 MAP kinase reduced the production of IL-5, but this appears to be due to a speci®c eect of p38 MAP kinase on the CD4 + CD45RO + memory subset (Mori et al., 1999; Schafer et al., 1999) . The eect of p38 MAP kinase in mouse memory CD4 + T cells remains unknown. The ERK signaling pathway does not appear to be essential for IL-2 production or proliferation of CD4 + T cells (Alberola-Ila et al., 1996) . In contrast to the JNK and p38 MAP kinase signaling pathways, the activation of the Ras/ERK pathway is required for IL-4 receptor function (e.g. STAT6 phosphorylation) and the dierentiation of CD4 + Th2 cells in vivo and in vitro (Yamashita et al., 1999) .
Together, these studies demonstrate that Th1 and Th2 dierentiation is not only determined by the presence or absence of speci®c transcription factors involved in the regulation of speci®c cytokine genes. The MAP kinase signaling pathways are dierentially regulated in the two subsets of eector CD4 + T cells and the regulation of these pathways is likely to play a key role in the balance of Th1/Th2 immune responses.
MAP kinases in CD8 + T cell activation and eector function
Upon activation CD8 + T cells proliferate with the help of IL-2 produced by CD4 + cells. The CD8 + cells produce IFNg and dierentiate into cytotoxic T cells that secrete perforin and granzyme. Very few studies have addressed the role of MAP kinases in CD8 + T cell function. This is probably because it is assumed that similar signaling mechanisms regulate the function of both types of T cells. However, since CD4 + and CD8 + T cells have dierent eector functions it is quite likely that the speci®c transcription factors and signaling pathways involved are also dierentially regulated. Recent studies that address the role and regulation of speci®c signaling components in CD8 + T cells support this concept (Carter and Murphy, 1999) . Analysis of the role of MAP kinase pathways in CD4 + and CD8 + T cells is critically important for our understanding of the in vivo immune response.
The phenotype of CD8 + T cells in mice de®cient of JNK remains unknown. Similarly, little is known about the speci®c role of ERK in CD8 + T cell function. However, analysis of pharmacological inhibition of the ERK pathway in CD8 + T cells suggests that this pathway is required for cytotoxic activity of most CD8 + T cells (Lilic et al., 1999) . p38 MAP kinase regulates IFNg production in CD8 + T cells as it does in CD4 + T cells . However, activation of the p38 MAP kinase pathway in vivo induces apoptosis in CD8 + T cells, but not in CD4 + T cells, demonstrating that activation of the same speci®c signaling pathway can have a dierent outcome in the two T cell subsets. Induction of death in CD8
+ T cells appears to be due to a reduction of Bcl-2 levels selectively in CD8 + T cells, although this eect is not mediated by inhibition of Bcl-2 gene expression but most likely by increased degradation (Merritt et al., 2000) . Thus, activation of p38 MAP kinase results in increased production of IFNg by CD4 + Th1 cells and CD8 + T cells, but also leads to a decreased number of eector CD8 + T cells. Clearance of in¯uenza virus in transgenic mice in which p38 MAP kinase is constitutively activated in CD4 + and CD8 + T cells is only slightly increased despite the increased IFNg production by these cells . This partial phenotype is likely due to the reduced number of antigen speci®c eector CD8 + T cells.
Targets of MAP kinase signal transduction pathways in T cells
The molecular mechanisms that are employed by MAP kinases to regulate T cell physiology are poorly understood. It is likely that MAP kinases target many dierent cellular processes. However, a focus for many studies has been the regulation of transcription factors.
Examples include the analysis of the eects of MAP kinases on the AP-1 and NFAT transcription factors. Some AP-1 proteins have been identi®ed as substrates of MAP kinases. Thus, JNK phosphorylates ATF2 (Gupta et al., 1995; Livingstone et al., 1995 ), cJun (DeÂ rijard et al., 1994 Hibi et al., 1993; Kyriakis et al., 1994) , JunD (Gupta et al., 1996; Kallunki et al., 1996) and JunB (Li et al., 1999) . The role of this phosphorylation in T cell physiology is unclear, but progress in our understanding has been achieved in recent studies. Thus, the phosphorylation of JunB by JNK is implicated in the expression of IL-4 by T cells (Li et al., 1999; RincoÂ n et al., 1997) . Phosphorylation of JunB appears to increase binding of this transcription factor to the IL-4 promoter in co-operation with c-Maf (Li et al., 1999) . In contrast, studies of c-Jun have not provided evidence for a major role of this transcription factor in T cells. Thus, c-Jun 7/7 T cells were found to develop normally (Chen et al., 1994) . However, it is possible that the loss of c-Jun may be complemented by other AP-1 proteins. A recent elegant study has examined the role of c-Jun phosphorylation using mice with a germ-line mutation of the two phosphorylation sites (Ser-63 and Ser-73 replaced with Ala residues) (Behrens et al., 1999) . It was found that this mutation caused no defect in activation or IL-2 secretion by peripheral T cells (Behrens et al., 2001) . However, it was found that anti-CD3 and TNFinduced thymocyte apoptosis was reduced. Further studies are required to more fully establish the role of MAP kinases and AP-1 proteins in T cells.
The NFAT group of transcription factors have been identi®ed as potential targets of signal transduction by JNK. However, the data presented in recent reports is contradictory. One group found that increased amounts of NFATc1 were detected in the nucleus of CD4 + T cells isolated from Jnk1 7/7 mice (Dong et al., 1998) . Following activation, similar amounts of NFATc1 were detected in the nucleus of wild-type and Jnk1 7/7 mice. The increased amount of nuclear NFATc1 was proposed to contribute to the increased expression of IL-4 by CD4 + T cells and the subsequent polarization to become Th2 CD4 + eector cells. No defects in the regulation of NFATc2 were found. Together, these data suggest that JNK may negatively regulate NFATc1, but not NFATc2. The observation that NFATc1
7/7
T cells exhibit defects in IL-4 expression, but not IL-2 expression, is consisted with the reported phenotype of these Jnk1 7/7 mice (Ranger et al., 1998; Yoshida et al., 1998) . It is therefore likely that NFATc2 contributes to the normal expression of IL-2 in NFATc1 7/7 and Jnk1 7/7 mice. The mechanism of the selective regulation of NFATc1 by JNK has recently been examined (Chow et al., 2000) . In vitro studies demonstrated that JNK binds and phosphorylates NFATc1, but not NFATc2. The phosphorylation of NFATc1 in vivo on these sites (in COS cells) was established by immunoblot analysis using phospho-speci®c antibodies. Mutational analysis demonstrated that the JNK phosphorylation sites on NFATc1 contribute to the regulation of the nuclear accumulation of this transcription factor in cultured BHK cells. The molecular mechanism was proposed to be mediated by an eect of this phosphorylation to disrupt the interaction of calcineurin with its docking site on NFATc1 (Chow et al., 2000) . Decreased phosphorylation by JNK was proposed to selectively promote the activation of NFATc1 by calcineurin. Signi®cantly, JNK activation in peripheral CD4 + T cells in response to co-stimulation is a delayed response (Weiss et al., 2000) . Thus, NFATc1 regulation by JNK is not a rapid response to co-stimulation, but most likely represents a`gating' mechanism that provides a threshold for responses to an immune challenge.
An independent investigation of the regulation of NFAT transcription factors by JNK has led to dierent conclusions. It was found that the treatment of total lymph node cells with phorbol ester plus ionomycin caused normal nuclear accumulation of NFATc1 in experiments using wild-type and Jnk2 7/7 mice (Behrens et al., 2001) . However, electrophoretic mobility shift analysis (EMSA) demonstrated that the Jnk2 7/7 nuclear extracts exhibited severe defects in NFAT DNA binding activity using a probe derived from the NFAT site in the human IL-2 promoter (Behrens et al., 2001) . Defects in AP-1 binding were not detected. The loss of NFAT DNA binding activity has obvious implications for the reduced levels of IL-2 secretion by these cells (Sabapathy et al., 1999a) . In a separate study of wild-type and Jnk1 7/7 mice, it was found that nuclear extracts prepared from total lymph node cells activated with anti-CD3 plus anti-CD28 also exhibited defects in NFAT binding to the IL-2 promoter NFAT site . Supershift analysis demonstrated defects in the DNA binding activity of both NFATc1 and NFATc2. Together, these data suggest than JNK1 and JNK2 are both required for the function of NFATc1 and NFATc2 in the nucleus. This observation is consistent with the ®nding that the absence of either JNK1 and JNK2 in these studies led to reduced expression of IL-2. However it is unclear why, in the presence of high levels of costimulation, JNK de®ciency causes no eect on IL-2 expression, but does cause marked inhibition of NFAT DNA binding activity. Further experimentation will be required to determine the mechanism that accounts for the eects of JNK1 and JNK2 on the DNA binding activity of NFATc1 and NFATc2.
The dierences between these reports on the role of JNK in the function of NFAT transcription factors requires further study. Indeed, it is essential for progress in our understanding that the dierent observations outlined above are resolved. It is possible that these observations simply re¯ect dierent aspects of the same process, although it is dicult to reconcile these data at this time. It is also possible that the dierent observations re¯ect dierences in the experimental models that were used in these studies, including the design of the knockout mice; the pathogen status of the animals, and the analysis of puri®ed CD4 + T cells and mixed cell populations (e.g. total lymph node cells).
Concluding remarks
Although signi®cant progress has been made, there is much that we do not know concerning the role of MAP kinases in T cells. There are many gaps in our current knowledge and further investigation is needed to resolve the contrasting conclusions that have been drawn in some studies. Little is presently known about the speci®c targets of the MAP kinases in CD8 + and CD4 + T cells, and how these targets regulate speci®c genes. Important new areas for research include the study of the role of MAP kinases in speci®c T cell populations in an antigen-speci®c manner. In addition, studies comparing MAP kinases in memory versus naõÈ ve CD4 + and CD8 + T cells are required. Furthermore, the identi®cation of the speci®c stimuli (e.g. TcR, cytokines, and accessory molecules) that regulate MAP kinases during T cell development, activation and dierentiation represents another area that requires further study. We anticipate that signi®cant progress in our understanding of the role of MAP kinases in T cells will be achieved during the next few years.
